Peijia Medical Limited (HKG:9996)

Market Cap	3.64B
Revenue (ttm)	654.98M
Net Income (ttm)	-241.12M
Shares Out	665.68M
EPS (ttm)	-0.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	868,000
Average Volume	1,407,450
Open	5.43
Previous Close	5.58
Day's Range	5.33 - 5.59
52-Week Range	2.16 - 6.05
Beta	0.39
RSI	49.90
Earnings Date	May 23, 2025

About Peijia Medical

Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People’s Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve sys...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2012
• Employees: 1,047
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9996

Financial Performance

In 2024, Peijia Medical's revenue was 615.48 million, an increase of 39.53% compared to the previous year's 441.13 million. Losses were -226.58 million, -42.28% less than in 2023.

Financial numbers in CNY